Certara, Inc. (NASDAQ:CERT) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its stake in Certara, Inc. (NASDAQ:CERT – Get Rating) by 37.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,484 shares of the company’s stock after selling 5,043 shares during the period. SG Americas Securities LLC’s holdings in Certara were worth $136,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Certara by 6.2% during the third quarter. Vanguard Group Inc. now owns 10,652,509 shares of the company’s stock worth $141,466,000 after acquiring an additional 626,267 shares during the last quarter. BlackRock Inc. grew its position in Certara by 1.1% in the 1st quarter. BlackRock Inc. now owns 6,540,553 shares of the company’s stock valued at $140,491,000 after buying an additional 74,266 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in Certara by 58.7% in the 1st quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company’s stock valued at $68,755,000 after acquiring an additional 1,183,859 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Certara by 40.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,884,968 shares of the company’s stock valued at $38,312,000 after acquiring an additional 827,191 shares during the last quarter. Finally, State Street Corp lifted its holdings in Certara by 3.9% in the 3rd quarter. State Street Corp now owns 1,675,253 shares of the company’s stock valued at $22,247,000 after acquiring an additional 62,972 shares during the last quarter. Institutional investors own 75.45% of the company’s stock.

Insider Buying and Selling at Certara

In other Certara news, SVP Richard M. Traynor sold 5,000 shares of Certara stock in a transaction on Friday, April 14th. The stock was sold at an average price of $23.66, for a total transaction of $118,300.00. Following the completion of the transaction, the senior vice president now directly owns 182,368 shares of the company’s stock, valued at $4,314,826.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research analyst reports. Credit Suisse Group upped their price target on shares of Certara from $22.00 to $27.00 in a report on Monday, March 27th. TheStreet raised shares of Certara from a “d+” rating to a “c” rating in a research note on Monday, April 10th. Stephens assumed coverage on shares of Certara in a research note on Tuesday, April 11th. They set an “overweight” rating and a $28.00 price objective for the company. Morgan Stanley upped their price objective on shares of Certara from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Friday, March 10th. Finally, Barclays lowered shares of Certara from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $21.00 to $25.00 in a research note on Monday, April 3rd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Certara currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Certara Stock Down 3.2 %

CERT opened at $20.32 on Monday. Certara, Inc. has a 1-year low of $10.60 and a 1-year high of $24.96. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of 225.78, a P/E/G ratio of 2.15 and a beta of 1.57. The business has a 50 day moving average of $22.94 and a 200-day moving average of $19.01.

Certara (NASDAQ:CERT – Get Rating) last issued its earnings results on Monday, May 8th. The company reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. The firm had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $91.29 million. Certara had a return on equity of 5.97% and a net margin of 4.39%. Certara’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the business earned $0.11 earnings per share. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.37 earnings per share for the current year.

Certara Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.